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Abstract
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are the diseases that still challenges 
modern cardiology. Heart failure with preserved ejection fraction caused more than half of heart failure’s cases and 
AF is one of the most common co-morbidities, that can worsen prognosis. The following article presents the current 
knowledge regarding HFpEF and the significance of AF in this group of patients.
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Introduction
It is currently estimated that heart failure with preserved 
ejection fraction (HFpEF) affects about 5% of the popula-
tion over the age of 60 and accounts for more than half of 
diagnosed cases of heart failure (HF) [1]. As the population 
ages, this number will continue to increase in the coming 
years. Identification of a patient with HFpEF and estab-
lishing a correct diagnosis remains an important problem.
Atrial fibrillation (AF) is the most common type of ar-
rhythmia. In Poland, prevalence is estimated at 600– 
–699 cases per 100 000 people. Over the course of a life-
time, 1/3 of people will experience an AF episode. As with 
HFpEF, the incidence of this disease increases with age [2].
Atrial fibrillation is associated with increased risk of 
death (1.5–3.5 times), ischemic stroke (it is responsible for 
20–30% of strokes), left ventricular dysfunction (20–30% of 
patients with AF), but also cognitive impairment/dementia 
(regardless of the history of stroke), depression, significantly 
reduced quality of life and a higher risk of hospitalization [2].
Taking into consideration confirmed risks associated 
with AF, particular emphasis is now placed on the identifi-
cation of patients with asymptomatic AF. According to the 
European Society of Cardiology (ESC) guidelines, pulse 
screening is recommended for every person over 65 years 
of age and those at risk. New technologies, such as pres-
sure monitoring devices equipped with arrhythmia detec-
tion algorithms and smartwatch recording bands are also 
currently in use, but an electrocardiogram (ECG) is required 
to confirm arrhythmia and establish a definitive diagnosis.
The advantages of screening for AF include the possibil-
ity of early detection of the disease, implementation of anti-
coagulation in people at risk of stroke (therefore, preventing 
the consequences of stroke), delaying/preventing adverse 
remodeling of the atrium, or reduction in the risk of hospi-
talization as a result of decompensation due to arrhythmia.
In view of the fact that AF is associated with multi-mor-
bidity and the arrhythmia can run a different course de-
pending on a patient, it has been proposed to set up pa-
tient care teams, which would include doctors of various 
specialties, nurses, as well as committed family members. 
The guidelines also highlight the patient’s role in making 
decisions regarding the treatment of AF.
Patients with AF and heart failure represent a whole 
separate problem. First, the symptoms associated with ar-
rhythmia may mirror those of HF, making it difficult to une-
quivocally establish the cause. An irregular heartbeat can 
make echocardiographic assessment difficult and usually 
requires a higher number of measurements and averaging 
of the results; moreover, different cut-off points are postu-
lated for some variables. N-terminal pro-B-type natriuretic 
peptide (NT-pro BNP) concentrations are usually elevated 
in the presence of arrhythmia. Even though current ESC HF 
guidelines do not suggest different cut-off values for people 
with AF, this problem has been acknowledged. In clinical 
trials, either the number of participants with AF was limited 
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or higher values of natriuretic peptides were applied e.g., 
in PARAGON-HF trial > 900 pg/mL, for individuals with AF. 
The new HFA-PEFF algorithm [1] takes into account vari-
ous cut-off values for natriuretic peptides depending on 
the rhythm (sinus rhythm vs. AF).
Processes taking place in the heart of a person with 
HFpEF involving the left atrium, i.e., enlargement, remod-
eling and progressive fibrosis, are known risk factors for 
the development of AF. Moreover, diseases coexisting with 
HFpEF [i.e. diabetes, hypertension, chronic kidney disease 
(CKD), chronic obstructive pulmonary disease (COPD)] are 
also recognized risk factors for AF.
It should be emphasized that atrial fibrillation is one of 
those diseases that can occur at any stage of HFpEF — i.e., 
it may precede the diagnosis of HF, it can manifest itself 
at the time of diagnosis of HF (e.g., leading to acute heart 
failure as a result of cardiovascular decompensation by an 
arrhythmic episode), but it can also occur even many years 
after the diagnosis of HF. In view of numerous common risk 
factors, changes to the heart structure and coexistence of 
those two diseases, it is very difficult to assess the impact 
of one of them on the other.
Available literature data are inconsistent due to a number 
of factors. The proportion of people with AF in the studies var-
ies significantly [higher in observational studies, usually low-
er in randomized controlled trials (RCTs)]. Studies targeting 
the HFpEF population are ongoing or are yet to be published, 
so most of the information we have available comes from 
previous randomized trials involving different HF subgroups.
Nowadays, we know that the pathophysiology of HFpEF 
differs from that of heart failure with reduced ejection frac-
tion (HFrEF). Therefore, patients with HFpEF with statisti-
cally more comorbidities (as described above) were more 
likely to meet the criteria for exclusion from RCTs. On the 
other hand, in HFrEF atrial fibrillation is perceived as a re-
sult of disease progression, which may also result in the 
exclusion of such patients from RCTs. Therefore, AF groups 
are not representative of the size of their population. AF 
classification constitutes another problem. In some stud-
ies, only people with evidence of AF in an ECG on their first 
visit were included in the AF group. As a result, people with 
paroxysmal AF could be assigned to the control group.
Also, the criteria for the diagnosis of HFpEF in terms of 
left ventricular ejection fraction (LVEF) vary considerably 
depending on the study (LVEF ≥ 40% to ≥ 50%).
Despite the complexity of the problem, we describe the 
significance of AF in the population of patients with HFpEF 
based on selected publications.
The significance of atrial fibrillation  
in HFpEF
The analysis of the Framingham Heart Study [3] showed 
that for ‘de novo’ AF identified during follow-up, 37% of the 
population were diagnosed with heart failure in the course 
of the study and among the cases of newly diagnosed heart 
failure, more than half (57%) had AF.
Two studies from register analysis demonstrated a neg-
ative impact of AF on the course of HF. The Swedish Regis-
ter [4] analyzed more than 40 000 patients, 23% of whom 
had HFpEF, 22% — HFmrEF and 55% HFrEF. The propor-
tion of individuals with AF was the highest in the HFpEF 
group, at 65%, followed by 60% in the HFmrEF group and 
53% in the HFrEF cohort. In all types of HF, patients with 
AF were older, with a longer history of heart failure, were 
more likely to have a history of stroke, TIA, or heart attack. 
In the above-mentioned study, AF was associated with an 
increased risk of death, hospitalization for HF or stroke re-
gardless of ejection fraction (including the group with nor-
mal LVEF). Similarly, Zafrir et al. [5] corroborated the trend 
that the highest percentage of AF is found in the HFpEF 
group (39% of this population). AF was associated with old-
er age but also reduced exercise tolerance and more pro-
nounced HF symptoms. Among this group, AF was associ-
ated with a higher risk of achieving the composite endpoint 
(defined as death, cardiac event or hospitalization due to 
HF) in the group of patients with preserved or mid-range 
ejection fraction — but not HFrEF.
Also, in the analysis of the CHARM clinical trial [6] AF 
was shown to be associated with a worse prognosis, espe-
cially in the group with preserved ejection fraction. In the 
CHARM study, the authors emphasized the significant con-
tribution of AF to cardiac risk in the HFpEF group. Moreover, 
they pointed out that not only ongoing arrhythmia but also 
newly diagnosed AF constitutes an adverse prognostic fac-
tor. Similar conclusions were made in the TOPCAT study [7].
Lam et al. [8] analyzed the results of heart catheteri-
zation in 94 people with HFpEF (LVEF ≥ 45%), 32 of whom 
had AF. They showed that AF was associated with lower 
peak VO2 values, higher NT-proBNP (NT-proBNP log) lev-
els, and greater LAVI in echocardiographic examination 
compared to individuals with sinus rhythm. Also, the he-
modynamic assessment showed higher mean pulmonary 
capillary wedge pressure (PCWP) despite similar E/e’ val-
ues found in echocardiographic examination and a trend 
(p = 0.06) towards increased left ventricular end-diastolic 
pressures in this group.
In people with HFpEF, AF may be associated with an 
up to a 2-fold increase in the risk of death [9]. Similar-
ly, Cheng et al. [10] demonstrated that the presence of 
AF was associated with a worse prognosis in HFpEF pa-
tients. A number of studies [5, 6, 8] pointed to symptoma-
ticity of the disease — patients with AF usually present with 
a higher New York Heart Association (NYHA) class compared 
to those with sinus rhythm and similar ejection fraction.
Not only the mere presence of arrhythmia but also 
its type is relevant in the context of coexistence with HF. 
Newly diagnosed AF (de novo) is associated with a worse 
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prognosis than already ongoing AF and this applies not 
only to the risk of stroke but also to total mortality or risk 
of hospitalization of cardiovascular causes [6, 7, 11]. Aus-
trian researchers [12] demonstrated the negative impact of 
persistent/permanent AF on mortality and hospitalization 
on a group of more than 250 patients but failed to show 
such a relationship in the case of paroxysmal arrhythmia.
An analysis of the Get With The Guidelines — Heart Fail-
ure (GWTG-HF) registry [13] with regard to rhythm control 
versus rate control in patients with AF and HFpEF patients 
showed higher annual mortality in the rate control group 
(37.5% vs. 30.8%, p < 0.01). Importantly, the vast major-
ity (13 825 people) were managed with rate control (vs. 
1857 in the rhythm-control group.
Kotecha et al. [14] in his meta-analysis found that the 
risk of death from any cause over a 2-year follow-up period 
is the highest in the group of patients with AF and HFrEF; 
however, the risk of stroke and hospitalization due to exac-
erbation of HF is similar irrespective of ejection fraction. In 
contradiction to these findings, a study by Son et al. [15] 
showed that AF was associated with greater mortality (car-
diovascular as well as all-cause) in the HFpEF group (but 
not HFmrEF or HFrEF) during the follow-up period (median 
duration of approx. 4 years).
Treatment of AF
A treatment scheme for patients with AF, contained in an 
“ABC”, was presented in 2020.
‘A’ stands for anticoagulation  
— avoiding stroke
The guidelines indicate new oral anticoagulants (NOAC) 
as the preferred anticoagulation therapy. Data from a me-
ta-analysis of randomized clinical trials with new oral an-
ticoagulants showed a 19% reduction in risk of significant 
strokes, more than 50% reduction in the risk of incidence 
of hemorrhagic stroke and a similar reduction in the risk 
of ischemic stroke compared to VKA [2].
The Loire Valley Atrial Fibrillation Project [16] did not 
demonstrate statistically significant differences with re-
gard to the number of strokes/transient iachemic attacks 
(TIAs) or deaths depending on LVEF, although these num-
bers were increased in both HF groups. It is worth noting, 
however, that patients with AF and HFpEF received more 
points on the CHADS2 and CHA2DS2-VASc scales, which is 
not surprising given the higher number of diseases usually 
coexisting with HFpEF. Nevertheless, only 335/585 (61.4%) 
people were anticoagulated.
The ESC guidelines also highlight the role of scales 
used for the assessment of bleeding risk to identify vulner-
able patients, but even in such cases, it is recommended 
to initiate anticoagulation with more frequent control and 
elimination of possible modifiable risk factors for bleeding.
‘B’ — better symptom control
The ongoing discussion on the effectiveness and safety 
of rhythm control versus rate control strategies resulted 
in changes to the atrial fibrillation guidelines, where the 
roles of heart rhythm control and rate control strategies 
have been equated.
In people with mild symptoms or asymptomatic, rate 
control remains the best option. Additionally, this strate-
gy is intended for people, in whom we have not been able 
to effectively restore the sinus rhythm or reduce the fre-
quency of AF episodes, as well as, those in whom the risk 
of ‘rhythm control’ strategy outweighs the possible bene-
fits of the therapy. Beta-blockers or non-dihydropyridine 
calcium channel blockers are the first-line agents for peo-
ple with HFpEF and AF, followed by digoxin if these agents 
are not effective.
RACE trial did not show significant differences with re-
gard to the NYHA class, the number of hospitalizations or 
clinical events between the subgroups of strict (HR < 80/ 
/min) vs. lenient (HR < 110/min) heart rate control. Thus, 
a control strategy aiming at HR < 110/min is acceptable if 
it does not cause symptoms [2].
In 2019, Sartipy [17] evaluated 9 000 HFpEF patients, 
nearly 53% of whom had persistent atrial fibrillation. He con-
firmed that AF is associated with a higher risk of death in the 
HFpEF population. Moreover, when analyzing mortality de-
pending on heart rate, unlike in sinus rhythm, he did not notice 
a significant correlation, especially after 2 years of follow-up 
[for heart rate > 90/min the hazard ratio is 1.78 (1.46–2.17); 
1.08 (0.80–1.46) and 0.73 (0.46–1.17) for follow-up time of 
0–2 years, 2–4 years and 4–6 years, respectively].
In the 2020 ESC guidelines, a rhythm control strategy 
is recommended to reduce the symptoms associated with 
AF and improve the quality of life (class IA). The rhythm con-
trol strategy is recommended especially in younger people 
with the first episode of AF, AF due to an ‘acute condition’, 
or short time from the diagnosis of AF, little atrial remode-
ling, and a small number of comorbidities.
In cases of paroxysmal AF or persistent AF with or with-
out risk factors for AF recurrence (i.e., significant LA vol. 
enlargement, advanced patient age, long AF duration, CKD 
and other cardiovascular risk factors), pulmonary vein abla-
tion is recommended if antiarrhythmic treatment is ineffec-
tive or not tolerated. In people with HFpEF and AF, amiodar-
one and dronedarone are the drugs of choice. The use of 
sotalol may also be considered but monitoring of QT and 
potassium levels, as well as, the elimination of other proar-
rhythmic factors are necessary (recommendation IIbA).
Maintaining sinus rhythm in people with HFpEF can be 
difficult, for example, due to old age, atrial remodeling and 
multiple comorbidities, which can make it more difficult 
to match suitable pharmacological treatment. However, 
a study from a Japanese center [18] showed that perform-
ing percutaneous AF ablation in people with HFpEF reduces 
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Table 1. Review of selected studies involving patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF)
Name Framingham Heart 
Study [3]
Sartipy — Swedish 
[17]
CHARM (Candesartan in 
Heart failure-Assessment 
of Reduction in Mortality 
and morbidity) [6]




Observational Observational RCT Observational RCT
Inclusion 
criteria
Newly diagnosed AF 
(group I) 
Newly diagnosed HF 
(including HFpEF if LVEF 
≥ 45%) (group II)
Permanent AF (past 
medical history of AF 
+ ECG evidence) 
HFpEF (LVEF ≥ 50%)
HFpEF (LVEF ≥ 40%)
AF in ECG on the first visit 
Patients with a history  
of AF but sinus rhythm  
in ECG were assorted  
to the non-AF group
HFpEF (LVEF ≥ 50%) HFpEF (LVEF ≥ 45%) 
3 groups: no history of 
AF, history of AF with-
out AF in ECG during 




1,737 patients with a di-
agnosis of de novo AF 
1,166 patients with a di-
agnosis of de novo HF 
[479 (41%) — HFpEF]
9,090 patients with 
HFpEF
7,599 patients with HF, in-
cluding 3,023 with HFpEF
23,644 patients with 





Approx. 8 years for HF 
events (7.5 ± 1.5 years 
and AF (7.5 ± 1.6 years)
Approx. 2.9 years 37.7 months 1.8 years (0.8–3.1) Approx. 3.3 years
Number of 
AF patients
In a population with 
newly diagnosed HF 
(1,166 patients) 32% 
were previously diag-
nosed with AF, 18% were 
diagnosed with AF within 
30 days from the diag-
nosis, 12% developed 
AF later
4,794 (52.7%) 670 (17%) in the HFrEF 
group and 478 patients 
(19%) in HFpEF group at the 
beginning of the study 
In the course of the study, 
392 patients developed 
AF episodes, including 5% 
from the HFpEF in the group 
population (129 patients)
Including 9081 
(38.4%) with the diag-
nosis of AF and 2,348 
(9,9%) with de novo 
diagnosis 
AF during follow-up 
In the HFpEF group — 
respectively, 43,2% 
with the diagnosis of 
AF and 9.5% with de 
novo AF
760 patients (43%) 
with a past medical 
history of AF (18%) or 
AF in ECG during the 
visit (25%) 
In 6.3% of patients 
AF was identified 
after randomization, 
including 85 patients 
with de novo AF (8.5% 
of the population with-
out AF)
Conclusions Group I: Among 1,737 
patients with newly diag-
nosed AF approx. 37% 
had also HF. Among that 
group — half had HFpEF 
Group II: among 1,166 
patients with de novo HF 
57% had also AF. Diag-
nosis of AF was more 
often associated with 
the diagnosis of HFpEF 
(32% vs. 23% in case  
of HFrEF)
Coexistence of AF and 
HF was associated with 
greater risk of death — 
in the group with  
de novo diagnosis  
of HFpEF and AF  
(HR 1.83, 95% CI)
During follow-up 
2,639 patients from 
the AF group died 
(55%). 1-year and 
5-year survival in 
the group with sinus 
rhythm vs. AF was, 
respectively, 84% 
vs. 76% and 51% 
vs. 38% (log-rank 
p < 0.001) 
Coexistence of AF 
and HFpEF was 
associated with 
increased risk of 
death (HR 1.21, 
p < 0.001)
AF was associated with 1.7- 
-fold increase in the risk of 
death from cardiovascular 
causes or risk of hospitali-
zation due to HF in patients 
with HFpEF 
In the group of patients with 
HFpEF during follow-up 34% 
had an event of HF exacer-
bation vs. 21% in patients 
with sinus rhythm 
Multivariate analysis 
showed that AF was an 
independent risk factor for 
cardiovascular death or 
hospitalization among pa-
tients with HFpEF 
(HR 1.32, 95% CI 1.06– 
–1.65, p = 0.015) but not 
with HFrEF (HR 1.12, 95% 
CI 0.97–1.29, p = 0.12) 
Patients with de novo diag-
nosis of AF had higher risk 
of morbidity and mortality 
irrespective of ejection 
fraction
History of AF in pa-
tients with HFpEF 
was associated with 
increased risk of 
all-cause death, hos-
pitalization due to HF 
or any other cause, as 
well as stroke 
(HR 1.11; 1.26; 1.16; 
1.91., respectively) 
De novo diagnosis of 
AF was associated 
with increased risk of 
all-cause death, hos-
pitalization due to HF 
or any other cause as 
well as stroke 
(HR 1.62; 1.96; 1.43; 
2.72, respectively)
Patients with AF in 
ECG had the highest 
risk of achieving pri-
mary endpoint (death 
due to cardiovascular 
causes, cardiac ar-
rest, hospitalization 
due to HF) or all-cause 
death (HR 1.34, 95% 
CI: 1.09–1.65,  
p < 0.006) 
In the group of 
patients with AF 
diagnosed after 
randomization, there 
was a 2.3-fold greater 
risk of achieving the 
endpoint 
(HR 2.32, 95% 
CI: 1.59–3.40, 
p < 0.0001). The risk 
was highest during 
the first 90 days from 
the episode of AF
CHARM — Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity; RCT — randomized controlled trials; HF — heart failure; LVEF — left ventricular ejection fraction; ECG — electrocar-
diogram; HFrEF — heart failure with reduced ejection fraction; HR — hazard ratio; CI — confidence interval
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the number of repeat hospitalizations due to exacerbation 
of HF (9% in the ablation group vs. 48% in the anti-arrhyth-
mic therapy group, log p = 0.0039).
‘C’ — cardiovascular risk factors  
and treatment of comorbidities
Treatment of concomitant diseases and cardiovascular risk 
factors affects the frequency of AF episodes both during 
pharmacotherapy as well as after effective ablation.
It is recommended that agents from specific groups [an-
giotensin-converting enzyme inhibitors (ACEI)/angiotensin 
receptor blockers (ARB), mineralocorticoid-receptor antag-
onists (MRA), statins] should be used if clinically indicated.
Summary
As described in the above article, atrial fibrillation and 
heart failure with preserved ejection fraction are common 
diseases, closely related i.a. due to the presence of mutual 
risk factors and etiology. However, their interrelationship 
requires further studies on patient groups representative 
of the population.
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